Abbott Laboratories (NYSE:ABT) Declares $0.63 Quarterly Dividend

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, June 12th. Stockholders of record on Wednesday, July 15th will be paid a dividend of 0.63 per share by the healthcare product maker on Monday, August 17th. This represents a c) annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th.

Abbott Laboratories has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 54 consecutive years. Abbott Laboratories has a payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Abbott Laboratories to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Abbott Laboratories Trading Up 0.0%

Shares of Abbott Laboratories stock opened at $93.97 on Monday. The business has a fifty day simple moving average of $89.21 and a 200-day simple moving average of $103.09. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm has a market cap of $163.69 billion, a price-to-earnings ratio of 26.32, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABT. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank boosted its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC grew its holdings in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its position in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.